1-11 of 11
Dung T. Le
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immunotherapy of MSI Cancer: Facts and Hopes

H. Catherine Wilbur, Dung T. Le, Parul Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1438–1447.
https://doi.org/10.1158/1078-0432.CCR-21-1935
Published: 15 April 2024
View article titled, Immunotherapy of MSI Cancer: Facts and Hopes
Open the PDF for Immunotherapy of MSI Cancer: Facts and Hopes in another window
Journal Articles

Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma

Lei Zheng, Ding Ding, Barish H. Edil, Carol Judkins, Jennifer N. Durham, Dwayne L. Thomas, II, Katherine M. Bever, Guanglan Mo, Sara E. Solt, Jessica A. Hoare, Raka Bhattacharya, Qingfeng Zhu, Arsen Osipov, Beth Onner, Katrina A. Purtell, Hongyan Cai, Rose Parkinson, Amy Hacker-Prietz, Joseph M. Herman, Dung T. Le, Nilofer S. Azad, Ana M.C. De Jesus-Acosta, Alex B. Blair, Victoria Kim, Kevin C. Soares, Lindsey Manos, John L. Cameron, Martin A. Makary, Matthew J. Weiss, Richard D. Schulick, Jin He, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Elizabeth Sugar, Elizabeth M. Jaffee, Daniel A. Laheru
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1278–1286.
https://doi.org/10.1158/1078-0432.CCR-20-2974
Published: 01 March 2021
View article titled, Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma
Open the PDF for Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

Annie A. Wu, Katherine M. Bever, Won Jin Ho, Elana J. Fertig, Nan Niu, Lei Zheng, Rose M. Parkinson, Jennifer N. Durham, Beth Onners, Anna K. Ferguson, Cara Wilt, Andrew H. Ko, Andrea Wang-Gillam, Daniel A. Laheru, Robert A. Anders, Elizabeth D. Thompson, Elizabeth A. Sugar, Elizabeth M. Jaffee, Dung T. Le
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5129–5139.
https://doi.org/10.1158/1078-0432.CCR-20-1025
Published: 01 October 2020
View article titled, A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Open the PDF for A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer

Takahiro Tsujikawa, Todd Crocenzi, Jennifer N. Durham, Elizabeth A. Sugar, Annie A. Wu, Beth Onners, Julie M. Nauroth, Robert A. Anders, Elana J. Fertig, Daniel A. Laheru, Kim Reiss, Robert H. Vonderheide, Andrew H. Ko, Margaret A. Tempero, George A. Fisher, Michael Considine, Ludmila Danilova, Dirk G. Brockstedt, Lisa M. Coussens, Elizabeth M. Jaffee, Dung T. Le
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3578–3588.
https://doi.org/10.1158/1078-0432.CCR-19-3978
Published: 15 July 2020
View article titled, Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Open the PDF for Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade

Andrew Georgiadis, Jennifer N. Durham, Laurel A. Keefer, Bjarne R. Bartlett, Magdalena Zielonka, Derek Murphy, James R. White, Steve Lu, Ellen L. Verner, Finey Ruan, David Riley, Robert A. Anders, Erika Gedvilaite, Sam Angiuoli, Siân Jones, Victor E. Velculescu, Dung T. Le, Luis A. Diaz, Jr, Mark Sausen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (23): 7024–7034.
https://doi.org/10.1158/1078-0432.CCR-19-1372
Published: 02 December 2019
View article titled, Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Open the PDF for Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade in another window
Includes: Supplementary data
Journal Articles

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

Dung T. Le, Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy Kindler, Andrea Wang-Gillam, Paul Oberstein, Michael A. Morse, Herbert J. Zeh, III, Colin Weekes, Tony Reid, Erkut Borazanci, Todd Crocenzi, Noelle K. LoConte, Benjamin Musher, Dan Laheru, Aimee Murphy, Chan Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5493–5502.
https://doi.org/10.1158/1078-0432.CCR-18-2992
Published: 13 September 2019
View article titled, Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Open the PDF for Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) in another window
Includes: Supplementary data
Journal Articles

Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors

Nicolas J. Llosa, Brandon Luber, Ada J. Tam, Kellie N. Smith, Nicholas Siegel, Anas H. Awan, Hongni Fan, Teniola Oke, JiaJia Zhang, Jada Domingue, Elizabeth L. Engle, Charles A. Roberts, Bjarne R. Bartlett, Laveet K. Aulakh, Elizabeth D. Thompson, Janis M. Taube, Jennifer N. Durham, Cynthia L. Sears, Dung T. Le, Luis A. Diaz, Drew M. Pardoll, Hao Wang, Robert A. Anders, Franck Housseau
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (17): 5250–5259.
https://doi.org/10.1158/1078-0432.CCR-19-0114
Published: 03 September 2019
View article titled, Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors
Open the PDF for Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan

Valerie Lee, Judy Wang, Marianna Zahurak, Elske Gootjes, Henk M. Verheul, Rose Parkinson, Zachary Kerner, Anup Sharma, Gary Rosner, Ana De Jesus-Acosta, Daniel Laheru, Dung T. Le, Aram Oganesian, Ellen Lilly, Thomas Brown, Peter Jones, Stephen Baylin, Nita Ahuja, Nilofer Azad
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6160–6167.
https://doi.org/10.1158/1078-0432.CCR-18-0421
Published: 13 December 2018
View article titled, A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
Open the PDF for A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan in another window
Includes: Supplementary data
Journal Articles

Microsatellite Instability as a Biomarker for PD-1 Blockade

Jonathan C. Dudley, Ming-Tseh Lin, Dung T. Le, James R. Eshleman
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 813–820.
https://doi.org/10.1158/1078-0432.CCR-15-1678
Published: 14 February 2016
View article titled, Microsatellite Instability as a Biomarker for PD-1 Blockade
Open the PDF for Microsatellite Instability as a Biomarker for PD-1 Blockade in another window
Journal Articles

Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed

Dung T. Le, Elizabeth M. Jaffee
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6061–6063.
https://doi.org/10.1158/1078-0432.CCR-13-2424
Published: 14 November 2013
View article titled, Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed
Open the PDF for Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed in another window
Includes: Supplementary data
Journal Articles

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

Dung T. Le, Dirk G. Brockstedt, Ran Nir-Paz, Johannes Hampl, Shruti Mathur, John Nemunaitis, Daniel H. Sterman, Raffit Hassan, Eric Lutz, Bentley Moyer, Martin Giedlin, Jana-Lynn Louis, Elizabeth A. Sugar, Alice Pons, Andrea L. Cox, Jordana Levine, Aimee Luck Murphy, Peter Illei, Thomas W. Dubensky, Jr, Joseph E. Eiden, Elizabeth M. Jaffee, Daniel A. Laheru
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3): 858–868.
https://doi.org/10.1158/1078-0432.CCR-11-2121
Published: 31 January 2012
View article titled, A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Open the PDF for A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction in another window
Includes: Supplementary data